|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
July/August 2004FeaturesLeading Edge Pharmacogenomics: Where Will It Take Us?Until now, drug research has focused on developing blockbusters to treat millions of people. Pharmaco-genomics works from the inside out: Researchers use genetic information to interpret disease pathways and create drugs for small, likely-to-respond populations. How it affects payers and patients. Benefit Design Biotech Injectable Drugs: Clinical Applications and Financial EffectsBiotech injectables rarely fit traditional drug benefit designs, potentially undermining a health plan’s goals. The authors, employee-benefit consultants, present actuarial models. Business Follow the Money: How Biotech’s Funding Shapes Its DirectionWhich source of funding – venture capitalists or pharmaceutical makers – provides the most innovative and useful path for a small biotech company? Specialty Pharmacy: New Guise for an Old Feud?Some specialists depend on the markup on injectables. To contain costs, health plans move control of biologic distribution from physicians to specialty pharmacies. Welcome back to the plan-provider turf wars of the ’90s. Reimportation and Biotech: A Germinating Crisis?Reimportation doesn’t pose a safety threat only with traditional drugs. There’s profit potential – and danger – in counterfeit biologics. Clinical Focus Targeted IgE Therapy for Patients With Moderate to Severe AsthmaBradley E. Chipps, MD, and Patricia L. Marshik, PharmD, review the clinical benefits of IgE-blocker therapy and who stands to benefit from it. DepartmentsEditor's Memo Objects in Our Mirror Are Closer Than They Appear
Michael D. Dalzell Editorial Pharmacogenomics and “Pharmacoecogenomics”
David B. Nash, MD, MBA Drugs and Diagnostics Biomarkers Gain Prominence In Drug Discovery and Development
Bob Carlson Discourse: Regulatory Government Pushes To Oversee Potential Recipes for BioterrorismFeds seek controls on publishing a virtual how-to for bioterrorists. Biotech Business E&Y: Productivity Will Move Biotechs to ProfitabilityNew report sees profitability in biotech industry by 2008. In the Pipeline Biotech Pipeline Set For Future Sales GrowthBiotech pipeline thrives, setting stage for future sales growth. |
|||||